2016 Update
Key population
This new edition and fully updated publication replaces the 2012 UCG and is being circulated free of charge to all public and private sector prescribers, pharmacists, and regulatory authorities in the country
Progress report of the Human Rights Council Advisory Committee (A/HRC/33/53) (Advance edited version)
This is a report from a National, representative household survey carried out in Botswana in 2012 – 2014. The study was carried out on behalf of the Norwegian Federation of Organisations of Disabled Persons (FFO), Southern Africa Federation of the Disabled (SASFOD) and Botswana Federation of Disab...led People (BOFOD). The study was led by Professor Tlamelo Mmatli of the University of Botswana, in collaboration with SINTEF Technology and Society. The study would not have been possible without a strong commitment from the Office of the President of Botswana and support from the Central Statistical Office. The study presents a broad picture of the situation among individuals with disability and households with disabled members in Botswana. It offers comparison with individuals without disability and households without disabled members, between provinces and between genders and locations (urban/rural). The study reveals that households with disabled members and individuals with disability score lower on a range on indicators on level of living.
more
Tune into Kids | UNICEF |
United and proud for the next generation
Standard Treatment Guideline
Standard Treatment Guideline
Strengthening Community responses to HIv Treatment and Prevention
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA ...guidelines.
The 2016 interim update to the 2015 BHIVA antiretroviral guidelines has been published online to include tenofovir-alafenamide/emtricitabine as a preferred NRTI backbone for first-line therapy. Changes were based on new data and the consensus opinion of the writing committee. All changes to the guideline are highlighted and include updates to the chronic kidney disease and bone disease sections of special populations and some small changes to managing virological failure.
The 2019 interim statement provides updated advice on treatment with two-drug regimens
more